Walleye Capital
BBIO icon

Walleye Capital’s BridgeBio Pharma BBIO Stock Holding History

Walleye Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$961K Hold
12,900
– – ﹤0.01% 2158
2026
Q1 		$958K Sell
12,900
-2,100
-14% -$152K ﹤0.01% 2115
2025
Q4 		$1.15M Buy
15,000
+8,500
+131% +$558K ﹤0.01% 2331
2025
Q3 		$338K Sell
6,500
-7,200
-53% -$351K ﹤0.01% 2914
2025
Q2 		$592K Buy
13,700
+5,600
+69% +$204K ﹤0.01% 2495
2025
Q1 		$280K Sell
8,100
-15,000
-65% -$506K ﹤0.01% 3006
2024
Q4 		$634K Buy
23,100
+2,400
+12% +$62K ﹤0.01% 2794
2024
Q3 		$527K Sell
20,700
-7,700
-27% -$202K ﹤0.01% 3251
2024
Q2 		$719K Buy
28,400
+21,900
+337% +$599K ﹤0.01% 3159
2024
Q1 		$201K Buy
+6,500
New +$221K ﹤0.01% 3975
2023
Q4 		– Sell
-10,900
Closed -$287K – 4932
2023
Q3 		$287K Buy
10,900
+8,400
+336% +$238K ﹤0.01% 3274
2023
Q2 		$43K Sell
2,500
-3,400
-58% -$51.2K ﹤0.01% 3665
2023
Q1 		$97.8K Buy
+5,900
New +$68.8K ﹤0.01% 2940

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Walleye Capital's BBIO Position: Q2 2026 in Review

Walleye Capital reduced its BridgeBio Pharma (BBIO) stake by 99% in Q2 2026, selling an estimated $15.9M and leaving 1,535 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #3830.

Walleye Capital first reported a position in BBIO in Q1 2021 and has held it in 13 quarters since. The position peaked at $17M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Walleye Capital held 1,535 shares of BridgeBio Pharma worth $114K as of Q2 2026.
  • Walleye Capital sold 227,058 BridgeBio Pharma shares in Q2 2026, an estimated $15.9M.
  • BridgeBio Pharma made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3830 holding.
  • Walleye Capital first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 13 quarters since.
  • Walleye Capital's BridgeBio Pharma position peaked at $17M in Q1 2026.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.